# Librela Injection for Canine Osteoarthritis: Efficacy, Dosing and Side Effects


## Key Takeaways

- Librela (bedinvetmab) is a canine anti-nerve growth factor (NGF) monoclonal antibody administered via subcutaneous injection, typically monthly, to manage osteoarthritis (OA) pain by neutralizing excess NGF that sensitizes pain receptors.
- Clinical trials demonstrate Librela's efficacy in improving objective measures of daily physical activity (via accelerometers) and subjective owner-reported pain and quality of life in obese dogs with OA.
- The standard dosing regimen is 1 mg/kg body weight, administered subcutaneously on Day 0 and Day 28, aligning with a monthly injection schedule, and requires veterinary prescription and administration due to precise dosing needs.
- While clinical trials report a favorable safety profile, perceived side effects in veterinary practice exist, though specific common adverse events are not detailed in the provided sources, necessitating discussion with a veterinarian.
- Librela is intended as part of a multimodal OA management plan, often used adjunctively with NSAIDs or other pain medications, and alongside non-pharmacologic therapies like weight management and omega-3 fatty acids.
- A definitive diagnosis of OA, often confirmed by imaging such as X-rays, is crucial before initiating Librela, as other conditions can mimic joint pain, and treatment decisions should be individualized by a veterinarian.

---

**Owner-facing triage summary:** If your [dog](/knowledge/veterinary-medicine/clinical-methods/dog) has been diagnosed with osteoarthritis (OA) and is showing signs of pain, stiffness, or reduced mobility, Librela (bedinvetmab) is a prescription medication given as an injection, usually once a month, to help manage that pain. It is not a cure, and it is not a first-line emergency treatment. You should contact your veterinarian to discuss whether Librela is appropriate for your dog, especially if your dog has difficulty standing, is reluctant to walk, or is showing changes in behaviour. Do not attempt to obtain or administer this medication without a veterinary prescription and a proper diagnosis.

This article provides a detailed, source-grounded review of Librela for canine osteoarthritis. We cover how it works, what the scientific evidence says about its efficacy, how it is dosed, and what side effects have been reported. We also discuss how it fits into a comprehensive pain management plan, as recommended by major veterinary organizations.

## Understanding Canine Osteoarthritis and the Need for New Treatments

Osteoarthritis is a progressive, degenerative joint disease that is extremely common in dogs. It involves the breakdown of cartilage, changes to the bone beneath the cartilage, and inflammation of the joint lining. This process leads to chronic pain, reduced mobility, and a decreased quality of life. While any dog can develop OA, it is particularly prevalent in senior pets and those carrying excess weight.

For many years, the cornerstone of OA management has been multimodal therapy. This approach combines non-pharmacological strategies, such as weight management and controlled exercise, with pharmacological interventions. Non-steroidal anti-inflammatory drugs (NSAIDs) have been the most prescribed drug class for this condition [<a href="#ref-1">1</a>]. However, NSAIDs are not always effective or tolerated. They can cause gastrointestinal, renal, or hepatic side effects, particularly in older dogs or those with other health conditions. This has created a clear need for alternative and adjunctive therapies.

According to a recent survey of veterinary practices, while NSAIDs are the most common drug class, other medications like gabapentin and bedinvetmab are also frequently prescribed [<a href="#ref-1">1</a>]. This indicates a shift towards more diverse, multimodal management strategies. The same survey highlighted that management patterns vary significantly among veterinarians based on their training and experience, with specialists more likely to use imaging to confirm OA [<a href="#ref-1">1</a>].

## What is Librela (Bedinvetmab)?

Librela is the brand name for the active substance **bedinvetmab**. It is a type of medication known as a monoclonal antibody. Specifically, it is a canine anti-nerve growth factor (NGF) monoclonal antibody [<a href="#ref-2">2</a>].

To understand how it works, it helps to know a bit about pain signalling. Nerve growth factor is a protein in the body that plays a key role in the development and maintenance of pain-sensing nerves. In an arthritic joint, NGF levels are often elevated. This excess NGF increases the sensitivity of pain receptors, making the joint more painful. Bedinvetmab works by binding to and neutralising this excess NGF. By doing so, it effectively "turns down the volume" on the pain signals coming from the arthritic joint.

This mechanism is fundamentally different from that of NSAIDs, which work by reducing inflammation. Because of this, Librela offers a targeted analgesic approach that may be beneficial for dogs that do not respond well to, or cannot tolerate, traditional anti-inflammatory medications. It is a targeted therapy designed specifically for the pain associated with canine OA.

## Efficacy of Librela: What the Evidence Shows

The efficacy of bedinvetmab has been evaluated in clinical trials, including a recent prospective, randomized, double-blind, placebo-controlled study [<a href="#ref-2">2</a>]. This type of study is considered the "gold standard" in medical research because it helps to eliminate bias and provides strong evidence for a treatment's effect.

### Objective Improvements in Activity

In a 56-day study involving 28 client-owned obese dogs with OA, researchers looked at the effect of bedinvetmab on daily physical activity [<a href="#ref-2">2</a>]. The dogs were randomly assigned to receive either bedinvetmab (at a dose of 1 mg/kg) or a placebo via subcutaneous injection on Days 0 and 28.

The study used accelerometers, which are small devices that track movement, to objectively measure the dogs' daily activity. The key finding was that the treatment group demonstrated **significant improvements in objective outcomes**, including the mean accelerometer-derived activity count per day [<a href="#ref-2">2</a>]. In simple terms, dogs receiving Librela moved more. This is a crucial finding because it provides measurable, unbiased evidence that the medication improves mobility, not just a subjective owner perception that the dog "seems better."

### Improvements in Pain and Quality of Life

Beyond just movement, the study also assessed pain and quality of life using the Canine Brief Pain Inventory (CBPI), a validated questionnaire for owners [<a href="#ref-2">2</a>]. The results showed that the treatment group also had significant improvements in these subjective outcomes. This means that owners of dogs treated with bedinvetmab reported that their dogs were in less pain and had a better quality of life compared to the owners of dogs in the placebo group.

This combination of objective and subjective improvements is powerful. It confirms that the increased activity measured by the accelerometers translates into real-world benefits that owners can see and feel in their dogs' daily behaviour.

### A Note on the Study Population

It is important to note that the study was conducted specifically in **obese dogs with OA** [<a href="#ref-2">2</a>]. Obesity and OA frequently coexist and can worsen each other's effects, leading to a more significant impact on mobility and muscle integrity [<a href="#ref-2">2</a>]. The fact that the medication was effective in this challenging patient group is encouraging. It suggests that Librela can be a valuable tool even in dogs where weight is a complicating factor. However, it is always important to discuss with your veterinarian whether these results are likely to apply to your dog's specific situation.

## Dosing and Administration of Librela

Librela is a prescription medication and must be administered by a veterinarian. It is given as a subcutaneous injection, which means it is injected under the skin.

- **Standard Dose:** The standard dose used in the clinical trial was **1 mg/kg** of body weight [<a href="#ref-2">2</a>].
- **Frequency:** In the study, the injection was given on Day 0 and then again on Day 28 [<a href="#ref-2">2</a>]. This aligns with the standard clinical recommendation of a monthly injection. Your veterinarian will determine the exact dosing schedule for your dog.
- **Administration:** The injection is typically given in a clinic setting. Your veterinarian will weigh your dog to calculate the precise dose needed.

It is vital that you do not attempt to dose or administer this medication yourself. The dose is calculated based on your dog's exact weight and health status. Incorrect dosing could lead to reduced efficacy or an increased risk of side effects.

## Side Effects and Safety Profile

As with any medication, it is important to be aware of the potential side effects of Librela. The available research and veterinary surveys provide some insight into its safety profile.

### Reported Side Effects in Clinical Trials

The 56-day trial on obese dogs reported that bedinvetmab offers a **favorable safety profile** [<a href="#ref-2">2</a>]. However, "favorable" does not mean "no side effects." It means that the side effects observed were manageable and the benefits of treatment were judged to outweigh the risks.

The specific types of side effects were not detailed in the abstract summary of the study [<a href="#ref-2">2</a>]. However, the study's conclusion that it has a favorable safety profile, particularly in overweight and geriatric patients where NSAIDs can be problematic, is a significant point in its favour [<a href="#ref-2">2</a>].

### Perceived Side Effects in Veterinary Practice

A recent cross-sectional survey of veterinarians aimed to report the **perceived adverse events** associated with bedinvetmab (Librela) and another medication, grapiprant [<a href="#ref-1">1</a>]. This is important because it captures real-world experiences from practising veterinarians, which can sometimes differ from what is seen in tightly controlled clinical trials.

The abstract summary for this survey notes that the secondary aim was to report these perceived side effects, but it does not list the specific side effects reported [<a href="#ref-1">1</a>]. This highlights a key limitation: while we know that veterinarians do perceive side effects, the most common ones are not specified in the available source material.

### What Does This Mean for Your Dog?

Because the specific side effects are not fully detailed in the approved source material, it is essential to have a detailed conversation with your veterinarian. They can provide you with the most up-to-date information on potential adverse reactions, which may include things like:

- Injection site reactions (pain, swelling, or redness)
- Lethargy or drowsiness
- Changes in appetite or thirst
- Vomiting or diarrhea (or diarrhoea)
- Neurological signs (in rare cases)

Your veterinarian can also help you weigh the risks and benefits for your individual dog. For example, a dog that has had bad reactions to NSAIDs might be a better candidate for Librela, despite the potential for other side effects.

## Librela in the Context of Multimodal Management

The management of canine OA is rarely a single-drug approach. The most effective plans are multimodal, meaning they combine several different types of treatment to target pain through different pathways.

The survey of veterinary practices confirmed that NSAIDs are the most prescribed drug class, but it also showed that medications like gabapentin and bedinvetmab are frequently used alongside them [<a href="#ref-1">1</a>]. This suggests that Librela is often used as part of a broader pain management strategy, not necessarily as a standalone replacement for all other therapies.

### The Role of Non-Pharmacologic Therapies

In addition to medications, non-pharmacologic treatments are a cornerstone of OA care. The same survey found that the most used nutraceutical and non-pharmacologic treatments were **omega-3 fatty acids** and **weight management** [<a href="#ref-1">1</a>].

- **Weight Management:** This is arguably the single most important factor in managing OA. Excess weight puts additional stress on already painful joints. The study on bedinvetmab specifically looked at obese dogs, highlighting the importance of this comorbidity [<a href="#ref-2">2</a>]. Weight loss alone can lead to significant improvements in mobility.
- **Omega-3 Fatty Acids:** These supplements have anti-inflammatory properties and can help support joint health.
- **Other Therapies:** Depending on your dog's needs, your veterinarian might also recommend physical therapy, hydrotherapy, acupuncture, or changes to your dog's environment (like providing ramps or orthopaedic bedding).

### How Librela Fits In

Librela works by targeting NGF, a specific pain pathway. NSAIDs work by reducing inflammation. Gabapentin works on nerve pain. By combining these different mechanisms, it is possible to achieve better pain control with lower doses of each drug, potentially reducing the risk of side effects from any single medication.

Your veterinarian might recommend Librela as:
- A first-line treatment for pain, especially if NSAIDs are contraindicated.
- An add-on therapy to an NSAID for dogs that are not getting adequate relief.
- A part of a comprehensive plan that includes weight loss and other non-drug therapies.

The decision on how to use Librela will depend on your dog's specific diagnosis, overall health, and how they respond to other treatments.

## At a Glance: Librela vs. Traditional NSAIDs

To help you understand the options, here is a comparison table based on the information from the approved sources. This is a general guide and not a substitute for professional veterinary advice.

| Feature | Librela (Bedinvetmab) | Traditional NSAIDs |
| :--- | :--- | :--- |
| **Mechanism of Action** | Targets and neutralises Nerve Growth Factor (NGF) to reduce pain signalling [<a href="#ref-2">2</a>]. | Reduces inflammation by inhibiting enzymes (COX) involved in the inflammatory process. |
| **Administration** | Subcutaneous injection, typically once a month [<a href="#ref-2">2</a>]. | Oral tablet or liquid, usually given daily. |
| **Efficacy** | Proven to improve activity, pain, and quality of life in a placebo-controlled trial [<a href="#ref-2">2</a>]. | Widely used and effective for many dogs, considered the most prescribed drug class for OA [<a href="#ref-1">1</a>]. |
| **Side Effect Profile** | Reported as a favorable safety profile in a clinical trial [<a href="#ref-2">2</a>]. Perceived side effects are reported by veterinarians, but specific common ones are not detailed in the sources [<a href="#ref-1">1</a>]. | Can be associated with gastrointestinal, renal, and hepatic side effects, especially in geriatric or overweight patients [<a href="#ref-2">2</a>]. |
| **Best For** | Dogs that do not tolerate NSAIDs, those with certain health conditions, or as part of a multimodal plan. May be particularly useful in obese patients [<a href="#ref-2">2</a>]. | Dogs that need daily, systemic anti-inflammatory control and can tolerate the medication. |
| **Role in Therapy** | A targeted analgesic for chronic OA pain, often used in combination with other therapies [<a href="#ref-1">1</a>]. | A primary, first-line drug class for managing OA pain and inflammation [<a href="#ref-1">1</a>]. |

## Veterinary Examination and Diagnostics

Before starting any treatment for OA, a proper veterinary diagnosis is essential. The survey of veterinarians found that **53% of respondents used imaging whenever possible to confirm OA** [<a href="#ref-1">1</a>]. This is a critical step because other conditions can cause similar signs.

### The Importance of Imaging

Imaging, such as X-rays (radiographs), is the most common way to confirm OA. It allows the veterinarian to see the structural changes in the joint, such as bone spurs, narrowing of the joint space, and changes in the bone. The survey noted that veterinarians with higher levels of training and more experience were more likely to use imaging [<a href="#ref-1">1</a>]. This suggests that while physical examination is important, imaging provides a more definitive diagnosis.

### The Diagnostic Process

A typical workup for a dog with suspected OA might include:
1.  **Physical and Orthopaedic Examination:** The vet will watch your dog move, feel the joints for swelling, pain, or crepitus (a grating sensation), and check the range of motion.
2.  **Neurological Examination:** To rule out spinal or nerve issues that can mimic joint pain.
3.  **Imaging:** X-rays of the affected joints to confirm the diagnosis and assess the severity [<a href="#ref-1">1</a>].
4.  **Other Tests:** In some cases, blood tests or joint fluid analysis may be recommended to rule out other conditions like infection or immune-mediated disease.

Getting a confirmed diagnosis is the first step to building an effective treatment plan. If your vet does not have imaging equipment, they may refer you to a specialist.

## Prevention and Long-Term Management

Osteoarthritis is a progressive disease, meaning it cannot be cured, only managed. However, there are steps you can take to help slow its progression and maintain your dog's quality of life.

### Preventative Strategies

- **Weight Control:** Maintaining a healthy body weight is the single most effective way to reduce stress on joints and prevent the onset or worsening of OA. The link between obesity and OA is well-established [<a href="#ref-2">2</a>].
- **Controlled Exercise:** Regular, low-impact exercise helps maintain muscle mass and joint mobility. Activities like swimming or leash walks are often better than high-impact running or jumping.
- **Nutrition:** A balanced diet, potentially supplemented with omega-3 fatty acids, can support joint health [<a href="#ref-1">1</a>].

### Long-Term Management Plan

Managing OA is a lifelong commitment. A successful long-term plan will likely involve:
- **Regular Veterinary Check-ups:** To monitor the disease's progression and adjust medications as needed.
- **Multimodal Therapy:** Combining medications like Librela with non-drug therapies [<a href="#ref-1">1</a>].
- **Home Modifications:** Making your home more comfortable for your dog, such as providing non-slip flooring, ramps for stairs or the car, and orthopaedic beds.
- **Monitoring:** Keeping a close eye on your dog's behaviour and activity levels. The use of objective measures like accelerometers in research highlights the value of tracking activity, and you can do this informally at home by noting how much your dog wants to go for walks or play [<a href="#ref-2">2</a>].

## Limitations and When to Contact a Veterinarian

This article provides a general overview of Librela based on the available scientific evidence. It is crucial to understand the limitations of this information.

**This article is educational and is not a substitute for veterinary diagnosis or treatment.**

The information presented here cannot predict how your individual dog will respond to Librela. Breed-level information, in particular, cannot predict individual responses. Every dog is different, and factors like age, genetics, overall health, and the severity of the OA will all influence the outcome.

You should contact your veterinarian immediately if you notice any of the following in your dog:
- **Signs of an allergic reaction:** Facial swelling, hives, difficulty breathing.
- **Severe vomiting or diarrhoea** that lasts more than 24 hours.
- **Lethargy or weakness** that is unusual for your dog.
- **Changes in appetite or thirst** that are significant.
- **Any new or worsening neurological signs:** Such as tremors, seizures, or difficulty walking.
- **Lack of improvement:** If your dog's pain or mobility does not improve after the first injection, or if it worsens at any point.

Always discuss any concerns with your veterinarian. They are the only person qualified to make medical decisions for your dog.

## Frequently Asked Questions

### 1. How quickly does Librela work in dogs?
While the approved studies show significant improvements over a 56-day period with injections on Days 0 and 28, individual responses can vary [<a href="#ref-2">2</a>]. Some dogs may show improvement within a few days, while others may take up to a month or more to show a noticeable change. Your veterinarian can advise you on what to expect.

### 2. How often does a dog need a Librela injection?
The standard protocol, as reflected in the clinical trial, is a subcutaneous injection once a month [<a href="#ref-2">2</a>]. In the study, dogs received injections on Day 0 and Day 28. Your veterinarian will set up a recurring schedule for your dog.

### 3. Can Librela be given with other pain medications?
Yes, Librela is often used as part of a multimodal approach. The survey of veterinarians showed that bedinvetmab is frequently prescribed alongside other non-NSAID medications like gabapentin, and it can be used with NSAIDs as well [<a href="#ref-1">1</a>]. However, this must always be decided and monitored by your veterinarian to ensure safety.

### 4. What is the biggest concern with Librela injections?
The biggest concern with any medication is the potential for side effects. While the clinical trial reported a favorable safety profile, the survey of veterinarians indicates that side effects are perceived in practice [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>]. The most common specific side effects are not detailed in the available sources, so it is important to discuss potential risks, such as lethargy, vomiting, or injection site reactions, with your vet.

### 5. Is Librela a steroid?
No, Librela (bedinvetmab) is not a steroid. It is a monoclonal antibody that targets nerve growth factor (NGF) [<a href="#ref-2">2</a>]. This is a different mechanism of action compared to corticosteroids, which are potent anti-inflammatory drugs with a different set of risks and benefits.

### 6. Can a dog be on Librela for life?
Osteoarthritis is a lifelong, progressive condition, so long-term management is often necessary. The studies on bedinvetmab have evaluated its use over a period of at least 56 days [<a href="#ref-2">2</a>]. The decision to use it long-term should be made in consultation with your veterinarian, who will need to monitor your dog's response and adjust the treatment plan over time.

### 7. Is Librela safe for dogs with kidney or liver disease?
The clinical trial highlighted that bedinvetmab offers a favorable safety profile, particularly in patients where NSAIDs may be limited, such as overweight and geriatric dogs [<a href="#ref-2">2</a>]. However, the specific safety of Librela in dogs with severe kidney or liver disease is not detailed in the approved sources. You must discuss your dog's full medical history with your veterinarian before starting this medication.

### 8. What happens if my dog misses a Librela injection?
If your dog misses a scheduled injection, you should contact your veterinarian for advice. They will likely recommend rescheduling the injection as soon as possible to maintain consistent pain control. You should not try to give a double dose to "catch up."

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "How quickly does Librela work in dogs?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "While the approved studies show significant improvements over a 56-day period with injections on Days 0 and 28, individual responses can vary. Some dogs may show improvement within a few days, while others may take up to a month or more to show a noticeable change."
      }
    },
    {
      "@type": "Question",
      "name": "How often does a dog need a Librela injection?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The standard protocol, as reflected in the clinical trial, is a subcutaneous injection once a month. In the study, dogs received injections on Day 0 and Day 28."
      }
    },
    {
      "@type": "Question",
      "name": "Can Librela be given with other pain medications?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, Librela is often used as part of a multimodal approach. The survey of veterinarians showed that bedinvetmab is frequently prescribed alongside other non-NSAID medications like gabapentin, and it can be used with NSAIDs as well. However, this must always be decided and monitored by your veterinarian."
      }
    },
    {
      "@type": "Question",
      "name": "What is the biggest concern with Librela injections?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The biggest concern with any medication is the potential for side effects. While the clinical trial reported a favorable safety profile, the survey of veterinarians indicates that side effects are perceived in practice. The most common specific side effects are not detailed in the available sources, so it is important to discuss potential risks with your vet."
      }
    },
    {
      "@type": "Question",
      "name": "Is Librela a steroid?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No, Librela (bedinvetmab) is not a steroid. It is a monoclonal antibody that targets nerve growth factor (NGF). This is a different mechanism of action compared to corticosteroids."
      }
    },
    {
      "@type": "Question",
      "name": "Can a dog be on Librela for life?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Osteoarthritis is a lifelong, progressive condition, so long-term management is often necessary. The decision to use it long-term should be made in consultation with your veterinarian, who will need to monitor your dog's response and adjust the treatment plan over time."
      }
    },
    {
      "@type": "Question",
      "name": "Is Librela safe for dogs with kidney or liver disease?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The clinical trial highlighted that bedinvetmab offers a favorable safety profile, particularly in patients where NSAIDs may be limited, such as overweight and geriatric dogs. However, the specific safety of Librela in dogs with severe kidney or liver disease is not detailed in the approved sources. You must discuss your dog's full medical history with your veterinarian."
      }
    },
    {
      "@type": "Question",
      "name": "What happens if my dog misses a Librela injection?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "If your dog misses a scheduled injection, you should contact your veterinarian for advice. They will likely recommend rescheduling the injection as soon as possible to maintain consistent pain control."
      }
    }
  ]
}
</script>

## Sources

<a id="ref-1"></a>[<a href="#ref-1">1</a>] [Variations in the management of canine osteoarthritis: a cross-sectional survey of veterinary practices.](https://pubmed.ncbi.nlm.nih.gov/42290771/)

<a id="ref-2"></a>[<a href="#ref-2">2</a>] [Efficacy of bedinvetmab on pain, activity, and body composition in obese dogs with osteoarthritis: A randomized double-blind placebo-controlled trial.](https://pubmed.ncbi.nlm.nih.gov/42245458/)

## Related Clinical & Scientific Guides

* [Immune-Mediated Polyarthritis IMPA: Joint Pain, Fever and Steroid Protocol](/knowledge/veterinary-medicine/orthopedic-mobility/immune-mediated-polyarthritis-impa-joint-pain-fever-and-steroid-protocol)
* [Hip Dysplasia in Dogs: Hip Replacement vs FHO vs Conservative Management](/knowledge/veterinary-medicine/orthopedic-mobility/hip-dysplasia-in-dogs-hip-replacement-vs-fho-vs-conservative-management)
* [Thermoregulating & Heated Dog Beds: Infrared Heat Safety, Temperature Calibration, and Arthritis Relief](/knowledge/veterinary-medicine/orthopedic-mobility/heated-dog-bed-senior-arthritis)